Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEC with Carboplatin for Recurrent Ovarian Cancer
NCT02672098Phase 1Completed
- Sponsor
- Loma Linda University
- Start
- Jul 2016
- Primary completion
- Apr 2023
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of carboplatin in ovarian cancer, primary peritoneal carcinoma (PPC) and fallopian tube carcinoma (PFTC), sponsored by Loma Linda University. Primary endpoint: Recurrence-free survival at 18 months. Started Jul 2016; status: completed.
02
Drugs
carboplatin
03
Conditions
ovarian cancerprimary peritoneal carcinoma (PPC)fallopian tube carcinoma (PFTC)
Beyond the preview
Go deeper on NCT02672098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02672098.